Earnings Releases·Oct 29, 2026, 7:00 AM ET

Novocure — Third Quarter 2026 Earnings Summary

Total net revenues rose 16% year-over-year to $193.4 million, driven by a 19% increase in global active patients, while the net loss narrowed to $10.4 million ($0.09/share) from $37.3 million in the prior year period.
Full-year 2026 guidance was raised to $736–$743 million in revenue and $24–$34 million in Adjusted EBITDA, reflecting improved gross margins of 77% and a clear path to profitability.
Active patient base reached a record 5,260 globally, with Optune Lua patients surging 83% year-over-year and Optune Pax receiving regulatory approval in Japan for locally advanced pancreatic cancer.
Strategic progress includes a clinical collaboration with Verastem Oncology for pancreatic cancer and anticipated milestones for FDA approval on brain metastases from non-small cell lung cancer in Q4 2026.